Brand Name
Oflomac 400
Generic Name / Composition
Ofloxacin 400 mg
Main Category
-
Antibiotic – Fluoroquinolone Class
Description
Oflomac 400 Tablet contains Ofloxacin 400 mg, a broad-spectrum fluoroquinolone antibiotic.
It works by blocking bacterial DNA gyrase and topoisomerase IV, enzymes necessary for DNA replication and repair, thereby killing bacteria.
It is prescribed for moderate to severe bacterial infections.
Uses / Indications
-
Respiratory tract infections (pneumonia, bronchitis)
-
ENT infections (sinusitis, otitis media, tonsillitis)
-
Urinary tract infections (UTI), cystitis, pyelonephritis
-
Gastrointestinal infections (infective diarrhea, dysentery, typhoid fever)
-
Skin & soft tissue infections
-
Bone & joint infections
-
Sexually transmitted infections (gonorrhea, chlamydia, pelvic infections)
Dosage (General Guidance)
(As prescribed by physician)
-
Adults: 400 mg once or twice daily, depending on severity
-
Duration: Typically 5–14 days depending on infection type
Route: Oral
Advice: Take with water, before or after meals; avoid dairy products, antacids, or supplements containing calcium/iron/zinc within 2 hours of dose
Side Effects
-
Nausea, vomiting, diarrhea, stomach pain
-
Headache, dizziness, insomnia
-
Rash, itching, photosensitivity
-
Rare but serious: Tendonitis/tendon rupture, seizures, peripheral neuropathy, QT prolongation
Precautions / Warnings
-
Not effective in viral infections (cold, flu)
-
Avoid in children, pregnancy, and breastfeeding (risk of joint/tendon damage)
-
Use with caution in elderly patients, seizure disorders, tendon problems, or heart rhythm disturbances
-
Avoid direct sunlight (photosensitivity risk)
-
Must complete full antibiotic course to prevent resistance
Drug Interactions
-
Antacids, calcium/iron/zinc supplements (↓ absorption)
-
Warfarin (↑ bleeding risk)
-
Corticosteroids (↑ tendon rupture risk)
-
Anti-arrhythmic drugs (↑ QT prolongation)
Packaging
-
Strip of 10 tablets
Manufacturer
Macleods Pharmaceuticals Ltd.
Mumbai, India
Reviews
There are no reviews yet.